company background image

Mercury Laboratories BSE:538964 Stock Report

Last Price


Market Cap







18 May, 2022


Company Financials
538964 fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance2/6
Financial Health6/6

538964 Stock Overview

Mercury Laboratories Limited develops, manufactures, markets, distributes, and sells pharmaceutical drugs, medicines, and formulations for mother and child healthcare in Asia, Africa, the United States, the United Kingdom, and internationally.

Mercury Laboratories Competitors













Price History & Performance

Summary of all time highs, changes and price drops for Mercury Laboratories
Historical stock prices
Current Share Price₹501.25
52 Week High₹827.50
52 Week Low₹440.00
1 Month Change0.25%
3 Month Change-15.45%
1 Year Change-32.51%
3 Year Change80.63%
5 Year Change15.90%
Change since IPO1,442.78%

Recent News & Updates

Shareholder Returns

538964IN PharmaceuticalsIN Market

Return vs Industry: 538964 underperformed the Indian Pharmaceuticals industry which returned -10.4% over the past year.

Return vs Market: 538964 underperformed the Indian Market which returned 10.6% over the past year.

Price Volatility

Is 538964's price volatile compared to industry and market?
538964 volatility
538964 Average Weekly Movement8.9%
Pharmaceuticals Industry Average Movement7.0%
Market Average Movement7.2%
10% most volatile stocks in IN Market10.0%
10% least volatile stocks in IN Market4.8%

Stable Share Price: 538964 is more volatile than 75% of Indian stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: 538964's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Indian stocks.

About the Company

1962660Rajendra Shah

Mercury Laboratories Limited develops, manufactures, markets, distributes, and sells pharmaceutical drugs, medicines, and formulations for mother and child healthcare in Asia, Africa, the United States, the United Kingdom, and internationally. It offers products in various segments, such as gynec, pediatric, surgeon, and physician. The company exports its formulations, such as anti-inflammatory, antimalarial, digestive, hypoglycemic, multivitamin, CNS, pain management, gynec, CVS, cold and cough, miscellaneous, and other formulations, as well as antibiotic, antifungal, and antiviral formulations.

Mercury Laboratories Fundamentals Summary

How do Mercury Laboratories's earnings and revenue compare to its market cap?
538964 fundamental statistics
Market Cap₹601.50m
Earnings (TTM)₹34.17m
Revenue (TTM)₹623.73m


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
538964 income statement (TTM)
Cost of Revenue₹271.05m
Gross Profit₹352.68m
Other Expenses₹318.51m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date


Earnings per share (EPS)28.48
Gross Margin56.54%
Net Profit Margin5.48%
Debt/Equity Ratio17.0%

How did 538964 perform over the long term?

See historical performance and comparison



Current Dividend Yield


Payout Ratio


Is Mercury Laboratories undervalued compared to its fair value and its price relative to the market?

Valuation Score


Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: 538964 (₹501.25) is trading below our estimate of fair value (₹813.19)

Significantly Below Fair Value: 538964 is trading below fair value by more than 20%.

Price To Earnings Ratio

PE vs Industry: 538964 is good value based on its PE Ratio (17.6x) compared to the Indian Pharmaceuticals industry average (21.4x).

PE vs Market: 538964 is good value based on its PE Ratio (17.6x) compared to the Indian market (20.6x).

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 538964's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: 538964 is good value based on its PB Ratio (1.5x) compared to the IN Pharmaceuticals industry average (2.6x).

Future Growth

How is Mercury Laboratories forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score


Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Mercury Laboratories has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has Mercury Laboratories performed over the past 5 years?

Past Performance Score


Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 538964 has high quality earnings.

Growing Profit Margin: 538964's current net profit margins (5.5%) are lower than last year (6.9%).

Past Earnings Growth Analysis

Earnings Trend: 538964's earnings have grown by 18.6% per year over the past 5 years.

Accelerating Growth: 538964's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 538964 had negative earnings growth (-20.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (12.5%).

Return on Equity

High ROE: 538964's Return on Equity (8.7%) is considered low.

Financial Health

How is Mercury Laboratories's financial position?

Financial Health Score


Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 538964's short term assets (₹366.8M) exceed its short term liabilities (₹153.6M).

Long Term Liabilities: 538964's short term assets (₹366.8M) exceed its long term liabilities (₹101.8M).

Debt to Equity History and Analysis

Debt Level: 538964 has more cash than its total debt.

Reducing Debt: 538964's debt to equity ratio has reduced from 33.8% to 17% over the past 5 years.

Debt Coverage: 538964's debt is well covered by operating cash flow (116.3%).

Interest Coverage: 538964's interest payments on its debt are well covered by EBIT (85.9x coverage).

Balance Sheet


What is Mercury Laboratories's current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 2/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: 538964's dividend (0.8%) is higher than the bottom 25% of dividend payers in the Indian market (0.35%).

High Dividend: 538964's dividend (0.8%) is low compared to the top 25% of dividend payers in the Indian market (1.58%).

Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, 538964 has been paying a dividend for less than 10 years.

Growing Dividend: 538964's dividend payments have increased, but the company has only paid a dividend for 7 years.

Earnings Payout to Shareholders

Earnings Coverage: With its low payout ratio (7%), 538964's dividend payments are thoroughly covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: With its low cash payout ratio (11.7%), 538964's dividend payments are thoroughly covered by cash flows.

Next Steps


How experienced are the management team and are they aligned to shareholders interests?


Average board tenure


Rajendra Shah (69 yo)

no data




Mr. Rajendra Ramanlal Shah has been the Managing Director of Mercury Laboratories Limited since March 31, 1992 and serves as its Chief Executive Officer and served as its Chairman of the Board until Februa...

CEO Compensation Analysis

Compensation vs Market: Rajendra's total compensation ($USD22.66K) is below average for companies of similar size in the Indian market ($USD38.54K).

Compensation vs Earnings: Rajendra's compensation has been consistent with company performance over the past year.

Board Members

Experienced Board: 538964's board of directors are considered experienced (7.4 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

Mercury Laboratories Limited's employee growth, exchange listings and data sources

Key Information

  • Name: Mercury Laboratories Limited
  • Ticker: 538964
  • Exchange: BSE
  • Founded: 1962
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: ₹601.500m
  • Shares outstanding: 1.20m
  • Website:

Number of Employees


  • Mercury Laboratories Limited
  • 2/13-14, Gorwa Industrial Estate
  • Gorwa Road
  • Vadodara
  • Gujarat
  • 390016
  • India


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/18 00:00
End of Day Share Price2022/05/18 00:00
Annual Earnings2021/03/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.